Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience.

Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience. Br J Dermatol. 2020 Feb 20;: Authors: Hwang S, Johnson A, Fabbro S, Hastings J, Haverkos B, Chung C, Porcu P, William B Abstract Primary cutaneous B-cell lymphomas (PCBCL) are rare extranodal lymphoproliferative disorders that present in the skin and seldom disseminate systemically. The World Health Organization - European Organization for Research and Treatment of Cancer (WHO-EORTC) define three PCBCL types: primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle-center lymphoma (PCFCL) are histologically low grade and clinically indolent; primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is clinically and histologically aggressive. Staging is based on number, size, and areas of distribution of skin lesions. PMID: 32078154 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research